Intranasal Chlorpheniramine for Early Symptomatic Treatment of COVID-19 and the Impact on Long-COVID

DOI record: { "DOI": "10.7759/cureus.82736", "ISSN": [ "2168-8184" ], "URL": "http://dx.doi.org/10.7759/cureus.82736", "author": [ { "affiliation": [], "family": "Ferrer", "given": "Gustavo", "sequence": "first" }, { "affiliation": [], "family": "Valerio-Pascua", "given": "Fernando", "sequence": "additional" }, { "affiliation": [], "family": "Alas-Pineda", "given": "César", "sequence": "additional" }, { "affiliation": [], "family": "Gaitán-Zambrano", "given": "Kristhel", "sequence": "additional" }, { "affiliation": [], "family": "Pavón-Varela", "given": "Dennis J", "sequence": "additional" } ], "container-title": "Cureus", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2025, 4, 21 ] ], "date-time": "2025-04-21T23:06:21Z", "timestamp": 1745276781000 }, "deposited": { "date-parts": [ [ 2025, 4, 21 ] ], "date-time": "2025-04-21T23:06:22Z", "timestamp": 1745276782000 }, "indexed": { "date-parts": [ [ 2025, 4, 22 ] ], "date-time": "2025-04-22T04:05:27Z", "timestamp": 1745294727966, "version": "3.40.4" }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2025, 4, 21 ] ] }, "language": "en", "link": [ { "URL": "https://www.cureus.com/articles/350279-intranasal-chlorpheniramine-for-early-symptomatic-treatment-of-covid-19-and-the-impact-on-long-covid", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.7759", "published": { "date-parts": [ [ 2025, 4, 21 ] ] }, "published-print": { "date-parts": [ [ 2025, 4, 21 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.3389/fphar.2021.633680", "article-title": "COVID-19: Famotidine, histamine, mast cells, and mechanisms", "author": "Malone RW", "doi-asserted-by": "publisher", "journal-title": "Front Pharmacol", "key": "ref1", "unstructured": "Malone RW, Tisdall P, Fremont-Smith P, et al.. COVID-19: Famotidine, histamine, mast cells, and mechanisms. Front Pharmacol. 2021, 12:633680. 10.3389/fphar.2021.633680", "volume": "12", "year": "2021" }, { "DOI": "10.3389/fcvm.2023.1202696", "article-title": "Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation", "author": "Salvucci F", "doi-asserted-by": "publisher", "journal-title": "Front Cardiovasc Med", "key": "ref2", "unstructured": "Salvucci F, Codella R, Coppola A, et al.. Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation. Front Cardiovasc Med. 2023, 10:1202696. 10.3389/fcvm.2023.1202696", "volume": "10", "year": "2023" }, { "DOI": "10.3390/ijms22115672", "article-title": "Could histamine H1 receptor antagonists be used for treating COVID-19?", "author": "Qu C", "doi-asserted-by": "publisher", "journal-title": "Int J Mol Sci", "key": "ref3", "unstructured": "Qu C, Fuhler GM, Pan Y. Could histamine H1 receptor antagonists be used for treating COVID-19?. Int J Mol Sci. 2021, 22:10.3390/ijms22115672", "volume": "22", "year": "2021" }, { "DOI": "10.1128/mbio.01088-24", "article-title": "The histamine receptor H1 acts as an alternative receptor for SARS-CoV-2", "author": "Yu F", "doi-asserted-by": "publisher", "journal-title": "mBio", "key": "ref4", "unstructured": "Yu F, Liu X, Ou H, et al.. The histamine receptor H1 acts as an alternative receptor for SARS-CoV-2. mBio. 2024, 15:e0108824. 10.1128/mbio.01088-24", "volume": "15", "year": "2024" }, { "DOI": "10.3390/life14020219", "article-title": "The bittersweet symphony of COVID-19: associations between TAS1Rs and TAS2R38 genetic variations and COVID-19 symptoms", "author": "Santin A", "doi-asserted-by": "publisher", "journal-title": "Life (Basel)", "key": "ref5", "unstructured": "Santin A, Spedicati B, Pecori A, et al.. The bittersweet symphony of COVID-19: associations between TAS1Rs and TAS2R38 genetic variations and COVID-19 symptoms. Life (Basel). 2024, 14:10.3390/life14020219", "volume": "14", "year": "2024" }, { "DOI": "10.1038/s41598-022-10747-2", "article-title": "Distribution of TAS2R38 bitter taste receptor phenotype and haplotypes among COVID-19 patients", "author": "Risso D", "doi-asserted-by": "publisher", "journal-title": "Sci Rep", "key": "ref6", "unstructured": "Risso D, Carmagnola D, Morini G, et al.. Distribution of TAS2R38 bitter taste receptor phenotype and haplotypes among COVID-19 patients. Sci Rep. 2022, 12:7381. 10.1038/s41598-022-10747-2", "volume": "12", "year": "2022" }, { "DOI": "10.1007/s00011-020-01422-1", "article-title": "Histamine receptors and COVID-19", "author": "Ennis M", "doi-asserted-by": "publisher", "journal-title": "Inflamm Res", "key": "ref7", "unstructured": "Ennis M, Tiligada K. Histamine receptors and COVID-19. Inflamm Res. 2021, 70:67-75. 10.1007/s00011-020-01422-1", "volume": "70", "year": "2021" }, { "DOI": "10.1096/fj.202000502", "article-title": "Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases", "author": "Li X", "doi-asserted-by": "publisher", "journal-title": "FASEB J", "key": "ref8", "unstructured": "Li X, Zhang C, Liu L, Gu M. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases. FASEB J. 2020, 34:6008-16. 10.1096/fj.202000502", "volume": "34", "year": "2020" }, { "DOI": "10.1186/s12879-024-10211-8", "article-title": "Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies", "author": "Valerio-Pascua F", "doi-asserted-by": "publisher", "journal-title": "BMC Infect Dis", "key": "ref9", "unstructured": "Valerio-Pascua F, Baires F, Sekhon AK, et al.. Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies. BMC Infect Dis. 2024, 24:1348. 10.1186/s12879-024-10211-8", "volume": "24", "year": "2024" }, { "DOI": "10.1038/s41467-023-44477-4", "article-title": "Molecular mechanism of antihistamines recognition and regulation of the histamine H(1) receptor", "author": "Wang D", "doi-asserted-by": "publisher", "journal-title": "Nat Commun", "key": "ref10", "unstructured": "Wang D, Guo Q, Wu Z, et al.. Molecular mechanism of antihistamines recognition and regulation of the histamine H(1) receptor. Nat Commun. 2024, 15:84. 10.1038/s41467-023-44477-4", "volume": "15", "year": "2024" }, { "DOI": "10.1016/j.heliyon.2023.e15772", "article-title": "Antihistamines as an early treatment for Covid-19", "author": "Morán Blanco JI", "doi-asserted-by": "publisher", "journal-title": "Heliyon", "key": "ref11", "unstructured": "Morán Blanco JI, Alvarenga Bonilla JA, Fremont-Smith P, Villar Gómez de Las Heras K. Antihistamines as an early treatment for Covid-19. Heliyon. 2023, 9:e15772. 10.1016/j.heliyon.2023.e15772", "volume": "9", "year": "2023" }, { "DOI": "10.2174/0118715230259623231111165759", "article-title": "An overview of antihistamines and their properties used for treatment of different diseases", "author": "Chaudhari R", "doi-asserted-by": "publisher", "journal-title": "Antiinflamm Antiallergy Agents Med Chem", "key": "ref12", "unstructured": "Chaudhari R, Gosavi S, Bornare P, et al.. An overview of antihistamines and their properties used for treatment of different diseases. Antiinflamm Antiallergy Agents Med Chem. 2023, 22:220-9. 10.2174/0118715230259623231111165759", "volume": "22", "year": "2023" }, { "DOI": "10.1016/j.ijporl.2017.07.045", "article-title": "Expression and localization of histamine H(1), H(2), and H(3) receptors in rat olfactory epithelium", "author": "Yu C", "doi-asserted-by": "publisher", "journal-title": "Int J Pediatr Otorhinolaryngol", "key": "ref13", "unstructured": "Yu C, Li L, Xia Q, Tang Y. Expression and localization of histamine H(1), H(2), and H(3) receptors in rat olfactory epithelium. Int J Pediatr Otorhinolaryngol. 2017, 101:102-6. 10.1016/j.ijporl.2017.07.045", "volume": "101", "year": "2017" }, { "DOI": "10.1096/fj.202400452R", "article-title": "Molecular mechanism of bitter taste receptor agonist-mediated relaxation of airway smooth muscle", "author": "Conaway S Jr", "doi-asserted-by": "publisher", "journal-title": "FASEB J", "key": "ref14", "unstructured": "Conaway S Jr, Huang W, Hernandez-Lara MA, et al.. Molecular mechanism of bitter taste receptor agonist-mediated relaxation of airway smooth muscle. FASEB J. 2024, 38:e23842. 10.1096/fj.202400452R", "volume": "38", "year": "2024" }, { "DOI": "10.1016/j.jsbmb.2021.105939", "article-title": "7-Ketocholesterol: Effects on viral infections and hypothetical contribution in COVID-19", "author": "Ghzaiel I", "doi-asserted-by": "publisher", "journal-title": "J Steroid Biochem Mol Biol", "key": "ref15", "unstructured": "Ghzaiel I, Sassi K, Zarrouk A, et al.. 7-Ketocholesterol: Effects on viral infections and hypothetical contribution in COVID-19. J Steroid Biochem Mol Biol. 2021, 212:105939. 10.1016/j.jsbmb.2021.105939", "volume": "212", "year": "2021" }, { "DOI": "10.14639/0392-100X-N1584", "article-title": "COVID-19 manifestation in the oral cavity - a narrative literature review", "author": "Kusiak A", "doi-asserted-by": "publisher", "journal-title": "Acta Otorhinolaryngol Ital", "key": "ref16", "unstructured": "Kusiak A, Cichońska D, Tubaja M, et al.. COVID-19 manifestation in the oral cavity - a narrative literature review. Acta Otorhinolaryngol Ital. 2021, 41:395-400. 10.14639/0392-100X-N1584", "volume": "41", "year": "2021" }, { "DOI": "10.1128/mbio.03436-21", "article-title": "Human nasal epithelial cells sustain persistent SARS-CoV-2 infection in vitro, despite eliciting a prolonged antiviral response", "author": "Gamage AM", "doi-asserted-by": "publisher", "journal-title": "mBio", "key": "ref17", "unstructured": "Gamage AM, Tan KS, Chan WO, et al.. Human nasal epithelial cells sustain persistent SARS-CoV-2 infection in vitro, despite eliciting a prolonged antiviral response. mBio. 2022, 13:e0343621. 10.1128/mbio.03436-21", "volume": "13", "year": "2022" }, { "DOI": "10.3389/fimmu.2018.01873", "article-title": "The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets", "author": "Thangam EB", "doi-asserted-by": "publisher", "journal-title": "Front Immunol", "key": "ref18", "unstructured": "Thangam EB, Jemima EA, Singh H, et al.. The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets. Front Immunol. 2018, 9:1873. 10.3389/fimmu.2018.01873", "volume": "9", "year": "2018" }, { "DOI": "10.1016/j.phymed.2020.153296", "article-title": "Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway", "author": "Ma Q", "doi-asserted-by": "publisher", "journal-title": "Phytomedicine", "key": "ref19", "unstructured": "Ma Q, Li R, Pan W, et al.. Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway. Phytomedicine. 2020, 78:153296. 10.1016/j.phymed.2020.153296", "volume": "78", "year": "2020" }, { "DOI": "10.1111/j.1365-2222.2008.02990.x", "article-title": "Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms", "author": "Roumestan C", "doi-asserted-by": "publisher", "journal-title": "Clin Exp Allergy", "key": "ref20", "unstructured": "Roumestan C, Henriquet C, Gougat C, et al.. Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms. Clin Exp Allergy. 2008, 38:947-56. 10.1111/j.1365-2222.2008.02990.x", "volume": "38", "year": "2008" }, { "DOI": "10.1016/j.ejphar.2021.173897", "article-title": "Repositioning of histamine H(1) receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2", "author": "Ge S", "doi-asserted-by": "publisher", "journal-title": "Eur J Pharmacol", "key": "ref21", "unstructured": "Ge S, Wang X, Hou Y, et al.. Repositioning of histamine H(1) receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2. Eur J Pharmacol. 2021, 896:173897. 10.1016/j.ejphar.2021.173897", "volume": "896", "year": "2021" }, { "DOI": "10.1016/j.pupt.2020.101942", "article-title": "Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients", "author": "Hogan Ii RB", "doi-asserted-by": "publisher", "journal-title": "Pulm Pharmacol Ther", "key": "ref22", "unstructured": "Hogan Ii RB, Hogan Iii RB, Cannon T, et al.. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. Pulm Pharmacol Ther. 2020, 63:101942. 10.1016/j.pupt.2020.101942", "volume": "63", "year": "2020" }, { "DOI": "10.7759/cureus.20980", "article-title": "Molecular modeling and preliminary clinical data suggesting antiviral activity for chlorpheniramine (chlorphenamine) against COVID-19", "author": "Black SD", "doi-asserted-by": "publisher", "journal-title": "Cureus", "key": "ref23", "unstructured": "Black SD. Molecular modeling and preliminary clinical data suggesting antiviral activity for chlorpheniramine (chlorphenamine) against COVID-19. Cureus. 2022, 14:e20980. 10.7759/cureus.20980", "volume": "14", "year": "2022" }, { "DOI": "10.2174/2772432817666220601162006", "article-title": "Chlorpheniramine, an old drug with new potential clinical applications: a comprehensive review of the literature", "author": "Rizvi SA", "doi-asserted-by": "publisher", "journal-title": "Curr Rev Clin Exp Pharmacol", "key": "ref24", "unstructured": "Rizvi SA, Ferrer G, Khawaja UA, Sanchez-Gonzalez MA. Chlorpheniramine, an old drug with new potential clinical applications: a comprehensive review of the literature. Curr Rev Clin Exp Pharmacol. 2024, 19:137-45. 10.2174/2772432817666220601162006", "volume": "19", "year": "2024" }, { "DOI": "10.18502/ajmb.v15i2.12022", "article-title": "Human T2R38 bitter taste receptor expression and COVID- 19: from immunity to prognosis", "author": "Bethineedi LD", "doi-asserted-by": "publisher", "journal-title": "Avicenna J Med Biotechnol", "key": "ref25", "unstructured": "Bethineedi LD, Baghsheikhi H, Soltani A, et al.. Human T2R38 bitter taste receptor expression and COVID- 19: from immunity to prognosis. Avicenna J Med Biotechnol. 2023, 15:118-23. 10.18502/ajmb.v15i2.12022", "volume": "15", "year": "2023" }, { "DOI": "10.1080/07391102.2023.2300128", "article-title": "Bitter taste receptors establish a stable binding affinity with the SARS-CoV-2-spike 1 protein akin to ACE2", "author": "Kumar SA", "doi-asserted-by": "publisher", "journal-title": "J Biomol Struct Dyn", "key": "ref26", "unstructured": "Kumar SA, Selvaa Kumar C, Dsouza N. Bitter taste receptors establish a stable binding affinity with the SARS-CoV-2-spike 1 protein akin to ACE2. J Biomol Struct Dyn. 2025, 43:3845-58. 10.1080/07391102.2023.2300128", "volume": "43", "year": "2025" }, { "DOI": "10.1691/ph.2021.0840", "article-title": "A hypothesis: Bitter taste receptors as a therapeutic target for the clinical symptoms of SARS-CoV-2", "author": "Kumar SA", "doi-asserted-by": "publisher", "journal-title": "Pharmazie", "key": "ref27", "unstructured": "Kumar SA, Cheng W. A hypothesis: Bitter taste receptors as a therapeutic target for the clinical symptoms of SARS-CoV-2. Pharmazie. 2021, 76:43-54. 10.1691/ph.2021.0840", "volume": "76", "year": "2021" }, { "DOI": "10.1002/alr.22692", "article-title": "Does phenotypic expression of bitter taste receptor T2R38 show association with COVID-19 severity?", "author": "Barham HP", "doi-asserted-by": "publisher", "journal-title": "Int Forum Allergy Rhinol", "key": "ref28", "unstructured": "Barham HP, Taha MA, Hall CA. Does phenotypic expression of bitter taste receptor T2R38 show association with COVID-19 severity?. Int Forum Allergy Rhinol. 2020, 10:1255-7. 10.1002/alr.22692", "volume": "10", "year": "2020" }, { "DOI": "10.2139/ssrn.4603627", "article-title": "Chlorpheniramine maleate displays multiple modes of antiviral action against SARS-CoV-2: a mechanistic study", "author": "Elshaier Y", "doi-asserted-by": "publisher", "journal-title": "bioRxiv", "key": "ref29", "unstructured": "Elshaier Y, Mostafa A, Valerio-Pascua F, et al.. Chlorpheniramine maleate displays multiple modes of antiviral action against SARS-CoV-2: a mechanistic study. bioRxiv. 2023, 10.2139/ssrn.4603627", "year": "2023" }, { "DOI": "10. 10.18103/mra.v10i3.2752", "article-title": "Intranasal chlorpheniramine maleate for the treatment of COVID- 19: translational and clinical evidence", "author": "Sanchez-Gonzalez M", "doi-asserted-by": "publisher", "journal-title": "Med Res Arch", "key": "ref30", "unstructured": "Sanchez-Gonzalez M, Westover J, Rizvi S, et al.. Intranasal chlorpheniramine maleate for the treatment of COVID- 19: translational and clinical evidence. Med Res Arch. 2022, 10. 10.18103/mra.v10i3.2752", "year": "2022" }, { "DOI": "10.21203/rs.3.rs-2167465/v1", "article-title": "Chlorpheniramine intranasal spray to accelerate COVID-19 clinical recovery in an outpatient setting: The ACCROS trials", "author": "Valerio-Pascua F", "doi-asserted-by": "publisher", "journal-title": "Res Squ", "key": "ref31", "unstructured": "Valerio-Pascua F, Mejia EJP, Tesch ML, et al.. Chlorpheniramine intranasal spray to accelerate COVID-19 clinical recovery in an outpatient setting: The ACCROS trials. Res Squ. 2022, 10.21203/rs.3.rs-2167465/v1", "year": "2022" }, { "DOI": "10.7759/cureus.10501", "article-title": "In vitro virucidal effect of intranasally delivered chlorpheniramine maleate compound against severe acute respiratory syndrome coronavirus 2", "author": "Westover JB", "doi-asserted-by": "publisher", "journal-title": "Cureus", "key": "ref32", "unstructured": "Westover JB, Ferrer G, Vazquez H, et al.. In vitro virucidal effect of intranasally delivered chlorpheniramine maleate compound against severe acute respiratory syndrome coronavirus 2. Cureus. 2020, 12:e10501. 10.7759/cureus.10501", "volume": "12", "year": "2020" } ], "reference-count": 32, "references-count": 32, "relation": {}, "resource": { "primary": { "URL": "https://www.cureus.com/articles/350279-intranasal-chlorpheniramine-for-early-symptomatic-treatment-of-covid-19-and-the-impact-on-long-covid" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Intranasal Chlorpheniramine for Early Symptomatic Treatment of COVID-19 and the Impact on Long-COVID", "type": "journal-article" }